Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Global Blood Therapeutics, Inc. | exhibit_311.htm |
| EX-23.1 - EXHIBIT 23.1 - Global Blood Therapeutics, Inc. | exhibit_231.htm |
| EX-32.1 - EXHIBIT 32.1 - Global Blood Therapeutics, Inc. | exhibit_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Global Blood Therapeutics, Inc. | exhibit_312.htm |
| EX-10.5 - EXHIBIT 10.5 - Global Blood Therapeutics, Inc. | exhibit105-hingshamofferle.htm |
| EX-10.6 - EXHIBIT 10.6 - Global Blood Therapeutics, Inc. | exhibit106-sinhaterminatio.htm |
| 10-K - 10-K - Global Blood Therapeutics, Inc. | a2015form10-k.htm |
| EX-4.3 - EXHIBIT 4.3 - Global Blood Therapeutics, Inc. | exhibit43-firstamendmentto.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Global Blood Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Schembri, Vice President, Finance and Administration of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | |
Date: | March 29, 2016 | By: | /s/ John Schembri | |
John Schembri | ||||
VP, Finance and Administration (Principal Financial and Accounting Officer) | ||||